Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

By sjmartinez • April 8, 2023

Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension. Pulm Circ. 2023 Apr 1;13(2):e12213. doi: 10.1002/pul2.12213. PMID: 37025209; PMCID: PMC10071306.

Tags: endophenotype, histology, idiopathic pulmonary fibrosis, pathophysiology, Publications, pulmonary vascular disease, Pulmonary, Critical Care & Sleep Medicine

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC,[...]

Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing

Lee Y, Feng J, Rahrooh A, Bui AAT, Cooper CB, Hsu JJ. Peak Oxygen Uptake Prediction From Resting and Submaximal Variables of Cardiopulmonary Exercise Testing.[...]